Genta starts Genasense melanoma combination study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genta has initiated a new clinical study to evaluate its Bcl-2 inhibitor Genasense (oblimersen) in patients with advanced melanoma, the company announces Nov. 29. The trial is the first follow-on study to Genta's Phase III advanced melanoma trial of Genasense plus dacarbazine. The new pilot study will evaluate safety, efficacy and pharmacokinetics of Genasense combined with Abraxis BioScience's Abraxane (paclitaxel protein-bound particles) and Schering-Plough's Temodar (temozolomide). Meanwhile, Genta saw a setback Dec. 8 when preliminary results of a Phase III study of Genasense in acute myeloid leukemia failed to reach the overall survival primary endpoint. The company's NDA for chronic lymphocytic leukemia has a user fee date of Jan. 29 (1Pharmaceutical Approvals Monthly November 2006, In Brief)...
You may also be interested in...
Genta appealing Genasense "not approvable"
Genta announces Feb. 6 that it will appeal FDA's December 2006 "not approvable" designation for use of its oncologic Genasense (oblimersen) in chronic lymphocytic leukemia. "The appeal will be filed pursuant to the Formal Dispute Resolution process that exists within FDA's Center for Drug Evaluation and Research," Genta stated, adding that it filed notice reserving its rights to appeal in December 2006 and expects to complete the filing of this appeal during the current calendar quarter. Genta received the not approvable letter for the CLL indication in mid-December. The firm is also investigating the Bcl-2 inhibitor's utility in melanoma; a Phase III combination study in advanced melanoma was initiated in November (1Pharmaceutical Approvals Monthly December 2006, In Brief)...
Genta submits new data to Genasense NDA
Genta's major amendment to its Genasense (oblimersen) NDA for chronic lymphocytic leukemia will extend the user fee goal by 90 days to Jan. 29, Genta said Oct. 30. New analyses "reinforce" the conclusion that Genasense increased durable complete remissions, the company said. Genta is working to counter an FDA advisory committee rejection of Genasense in September due to lack of evidence of clinical benefit...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: